-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 V5NyUmmcTMqBxYqxwC4P3PClJAIwDrvJME5K1mw65viSTbkrx6A/GhfBjwUwjaTJ
 Z5/IaaCzRS+IHq/LyDJlMA==

<SEC-DOCUMENT>0001193125-10-025604.txt : 20100209
<SEC-HEADER>0001193125-10-025604.hdr.sgml : 20100209
<ACCEPTANCE-DATETIME>20100209140041
ACCESSION NUMBER:		0001193125-10-025604
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20100208
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100209
DATE AS OF CHANGE:		20100209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CERUS CORP
		CENTRAL INDEX KEY:			0001020214
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				680262011
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21937
		FILM NUMBER:		10583516

	BUSINESS ADDRESS:	
		STREET 1:		2411 STANWELL DR
		CITY:			CONCORD
		STATE:			CA
		ZIP:			94520
		BUSINESS PHONE:		9252886000

	MAIL ADDRESS:	
		STREET 1:		2525 STANWELL DRIVE
		STREET 2:		STE 300
		CITY:			CONCORD
		STATE:			CA
		ZIP:			94520

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CERUS TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19960731
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K </B>
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman"
SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Date of Report (Date of earliest event reported): February&nbsp;8, 2010 </B></FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>CERUS CORPORATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as
specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0-21937</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>68-0262011</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission File No.)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2411 Stanwell Drive
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Concord, California 94520 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s
telephone number, including area code: (925)&nbsp;288-6000 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01. Other Events. </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;8, 2010, Cerus Corporation issued a press release announcing results of its Phase 1 clinical trial of the INTERCEPT Blood
System for Red Blood Cells. The press release, dated February&nbsp;8, 2010, entitled &#147;Cerus Corporation Reports Positive Outcome of Phase 1 Clinical Trial of INTERCEPT Red Blood Cells&#148; is attached hereto as Exhibit 99.1 and is incorporated
by reference herein. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibits </B></FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated February 8, 2010, entitled &#147;Cerus Corporation Reports Positive Outcome of Phase 1 Clinical Trial of INTERCEPT Red Blood
Cells.&#148;</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CERUS CORPORATION</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: February 8, 2010</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Kevin D. Green</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kevin D. Green</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Finance and Chief</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman"
SIZE="2">Accounting Officer</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated February 8, 2010, entitled &#147;Cerus Corporation Reports Positive Outcome of Phase 1 Clinical Trial of INTERCEPT Red Blood
Cells.&#148;</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px">

<IMG SRC="g94463g75p68.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cerus Corporation Reports Positive Outcome of Phase 1 Clinical Trial of INTERCEPT Red Blood Cells </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Data Supports Advancement of Product Development </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman"
SIZE="2">CONCORD, Calif.&#151;(BUSINESS WIRE)&#151;February 8, 2010&#151;Cerus Corporation (NASDAQ: CERS) announced today that its Phase 1 trial of red blood cells treated with the INTERCEPT Blood System met its primary endpoint, with preliminary
analysis demonstrating that greater than 75 percent of treated cells continued to circulate 24 hours following transfusion. The INTERCEPT red blood cell system is a pathogen inactivation treatment the company is developing to protect against
transmission of infectious diseases through red blood cell transfusions. An estimated 70&nbsp;million units of red blood cells are transfused worldwide each year. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;We are pleased with the results of this study, which provide support to advance the INTERCEPT red blood cell program into late-stage clinical studies in pursuit of European product approval,&#148;
said Dr.&nbsp;Laurence Corash, Cerus&#146; Chief Medical Officer. &#147;The data from this study met recommended criteria for a successful red cell recovery study and showed significant improvement over prior generations of the technology.&#148;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The randomized, single-blind, controlled, multi-center Phase 1 clinical trial of the INTERCEPT red blood cell system included 27 healthy
subjects at two clinical trial centers. Each subject received two transfusions of the subject&#146;s own red blood cells, one INTERCEPT-treated, and the other a control not treated for pathogen inactivation. The primary endpoint of the clinical
trial, a mean INTERCEPT red blood cell recovery of greater than 75 percent at 24 hours post-transfusion, was met. The INTERCEPT red blood cells had a recovery of 88% compared to 90% for control red blood cells, and both INTERCEPT-treated and control
red blood cells met the criteria for red blood cell recovery recommended by the U.S. Food and Drug Administration. The half-life of the red blood cells was also evaluated, and INTERCEPT-treated red cells were within the established reference range
of 28 to 35 days. The half-life of INTERCEPT red blood cells was 33 days compared to 40 days for control red blood cells according to the preliminary analysis. The investigators plan to submit data from the study for presentation at an upcoming
scientific congress. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;With pathogen inactivation of platelets and plasma currently in routine use, the advancement of our red blood cell
system will offer a comprehensive solution to transfusion-transmitted infections for all blood products,&#148; said Claes Glassell, President and Chief Executive Officer of Cerus. &#147;We expect that these results will facilitate further red blood
cell partnerships like the ones currently in place with Grifols and the German Red Cross.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cerus has a collaborative research program
with the military to develop pathogen inactivation technology. The pre-clinical studies that enabled this Phase I trial were supported by the U.S. Army Medical Research and Materiel Command under contract number W81XWH-08-1-0480. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">

<IMG SRC="g94463g67u19.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ABOUT CERUS </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman"
SIZE="2">Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a
broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action allows INTERCEPT treatment to inactivate both established transfusion threats, such as hepatitis,
HIV, West Nile virus and bacteria, as well as emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected
countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See http://www.cerus.com for more information. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This press
release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements relating to the clinical
development and commercialization of the INTERCEPT Blood System for red blood cells, potential future partnership opportunities available to the company and the potential commercial value of a comprehensive solution for transfusion-transmitted
infections. Words such as &#147;will,&#148; &#147;expect&#148; and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the company&#146;s current expectations. Actual results could
differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks and uncertainties involving commercial adoption and market acceptance of the INTERCEPT Blood System, the uncertainty of
future clinical trial results, as well as other risks detailed in the Cerus&#146; filings with, the Securities and Exchange Commission (SEC), including in Cerus&#146; quarterly report on Form 10-Q for the quarter ended September&nbsp;30, 2009, filed
with the SEC on November&nbsp;6, 2009. Additionally, unless the company can obtain red blood cell project funding, it will not be able to make substantial further progress toward INTERCEPT red blood cell commercialization. No pathogen inactivation
system has been shown to inactivate all pathogens. The views, opinions and/or findings contained in this press release should not be construed as an official Department of Army position, policy or decision unless so designated by other
documentation. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Cerus does not undertake any obligation to update any forward-looking statements as a result of
new information, future events, changed assumptions or otherwise. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contact: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Lainie Corten </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director, Global Communications&nbsp;&amp; Marketing </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cerus Corporation </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(925) 288-6319 </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g94463g67u19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g94463g67u19.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`*`"'`P$1``(1`0,1`?_$`*P```("`@,!`0``````
M``````D*!P@$!@`#!0(+`0$``@,!`0```````````````P@$!@<%"1````8"
M`@$"`P4&`0T``````0(#!`4&!P@1"0`2$R$4"C%182(C07&!%187-)'!,E)B
ML]-TM#5F=QH1``$#`P,"`@4'"P4```````$``@,1!`42!@<A""(3,6&1L91!
M48&ATB-4T3)BDJ(4=!46&`F3T]0V1O_:``P#`0`"$0,1`#\`?X\(A5;(]O6M
MF#\Q26L.+JCFK=#;*';?,3^NFH5`5RI;:*0Q2"DMEBU*/X;'.*6_Z@"H$U+M
MG2)!`QD/28@F(H>?=BO:`WCU+`TZ)\[NJ^4OOE05W-U'0NYFGQ'UFI3:R/U@
M=@3X_+E=G5Y^''/A%$F%?J)<`7/:/&FDNP&I>ZVH&T>5[G`4:H8_S3BF*"'D
M).R.BLXR30LT19U%G-846-R,DFP,S!,IC^OTE$?"(DV5>PW`F&<EV;%MZ:WY
MK/5=2.(\>Q=90EHAP$G%,Y9`[9=O*@['T(/2E,!D"\'`>.0^/E:M[=U?&/'V
M[[S9>Y69-F3LC&'OCMQ+$[S(V2C2YLFKHUX!JP=:TJK3;#[0>5^2-E6.^MK/
MQ+\3?"0L9+<NBE;Y4KXG!S71:.KF$BCSTI6A6GAVH:E"'QF;X`_<-"F.0_?P
M(AYX']ZO!GXC)_!2K8_[$>X#\-BOCH5T..U74]$HF2?9#>&X^";>B/B''\`%
MVZ:I\C^)@\CE[V.#V"K),K(?F;9OK^TYH^M2P]AO/LCJ218>,?.Z^81^PUQ^
MI27/[QTF+UA7VFK.']B<N5H+$VK4=C3"V+U,D9JG'CJW)4XJ\-08>8*+MDU>
M*_,NE!=%*U8D.LIP!!#SOG&W(>$Y2VG#O';S+B/%3RRL:)VM9)6&1T;B6M<\
M`$M)'B)I2M%73E+C3/<2;QGV1N22VER]O%#(]UNYSXJ31ME:`YS&$D!P!\(%
M?14*CV4>]3!^OU>1O6S&F79=K?B\7#=O(97RKJ+(?V^@#.C@FW-9)>AW.\/(
M'WC#P0KELFHH;\I"F-^7S?%SQ%&USV6P-MQB:N9SUMRE4\P8IM0."1%PJ#_Y
MME\XR."4C$2C19-O)P,_%K&`CN/?(-GK4X@"J1!$/"(9&^?>CK%UIV^JU';W
M">U]!#()K&;&UJA,=X^N]-R"C5WS-E*FKTU6,LOSH/4`DVBQF4@BR?)H/$3'
M1+Z_@1%:P_D:1RO1(B\R6,,C8B--IINV=.RJVJ3&Z(1SAJV=LGLI&TVW76.B
MCNDG/`M5GA7J"A#$613,'`D6W6N:D*[79:;BJM.W:1C6HN&E4K*U?;STXJ!R
M%!E&+VJ<K5>3<F*83<NW[9+@H_GYX`2(3N#.YW".P^VV1='\=ZW;BEV,PV=5
M;,E3M.-L;UF(Q;#H2,-'FL-IMK[,(UY6'>!/M%V)HY=^M)MEBJLTUR#SX16&
MW,[+=6=')K'M`RG.7&[9TS`Y.TQ!K5@VE2^6M@LG*I_,`=:L8YK@"[1B@.U5
M)_,)%9A'BHDH4%Q,F<"D55K#VB;BP,6I:R])78!)4PJ(O"+QUMU8DK\=B!?<
M`_\`:N%S=+VXL@9/[&8$%QZORB4#?#PBD34SM[PAN3J]M/LUBO"NSL6;4%+(
M##*N$;OC%E"9P>7C'./%<B3&-Z=2V5EESS5U>LRD8-62RK19236(@8A!'GPB
MKW]0]V/W?KRT5.&#'2S?:+:"ZL=?<`N67H/*5B8L;-PO:<@QJ!P$%)*JP9`0
MCC_$J,W(L%#E.0IB&(KF=6W7SCGKDU,HN&JTP1D<I3[!E>=C\JOQ-(7+,6<K
M"U+(7BWVNQNS+RLP1&8=K-8TBZRGRL>DF0!$XJJ*$1&O"*C>XNHL%LA<M.\D
MI5V!=Y!U6VIH&:JU:7YD6<O"U5LSF8+(<1'O_85<N&<["2B9SL/45)P[9ME#
M<'03,4BF.TZJ:ZWBVR][N.(J?:+;/&:GEIJ=8JR:[LS)FW8->47:ZK1$$6;5
M,@`FF0!`O(\B(B/+<UPEQ/N3.S[ES^!L+W.7):999F&1SM#&L;T<XM%&-`\+
M1Z.O5=<P7//,6U]OV^U=N;AR-CM^U#A%#`\1-9K>Z1W5C0\U>YSO$X^GITZ+
M$#4+5T```P'BO@/_``Z'_P`[;D?(!P/PP!3^F,)\+%]E9![AN<S_`.LSWQ<W
MVEC.=.-5W9!37P%C#TB`A^E5H]N;@?N4;II'`?Q`>?(9N`.%)VZ9-KX:GJMF
M-^MH!4L/<;SO;NUQ;LSE?7=2.'L<2%+V/,;T?%%7:TO'==95:K,7+]VSA8\[
MD[1NXDW:KY\=+YM=RJ4%W:YC^GU>DHCP4`#X>;YM7:6W-D89FWMJ6D=EA8WO
M<V)A<6M=(XO>1J<X^)Q)I6@KT`'1<]W?O/<^_<Y)N7>%Y)?YV5C&/FD#0]S8
MV!C`=#6@Z6-`K2IIU)/5>S::M6[Q6K!3+C!15GJ=KAI.NV:MSK%O)PL]`S+-
M:/EHB6CG::K5]'2+%P=)9)0IB*)G$!#@?-C6L)(GZ:*L6;53MW[D-!Z9+R*^
MNF+[-;IJMU]=VY=QT-+TS,XTNCO4`745!&8>X]GA9OE0$%781R/N";V">DBR
M/K3$DSP/5X8Y"F$<X9F2$1#[4U&>&1.0?O*82!_D\(G@F(`5DS*4."E:MP``
M_8`)$``_@'A%E>$2KW70BD7ZF+O#5*0I3_V@UD_,`<"/O4C&)E!'\3BD7G]W
MA$+S7W<W'6J7U8.^$GV`3*%,=91B)3"&O&4LB&*UJV-H26-C6<Q"V3EY+AC4
M:M=\:Q(1Y9,ADFR;UX8C@Y"N7*@$3\"*R+A%)PW537073(L@NB<JJ*R*I0.F
MJDH03$434(8!*8!$!`>0\(H?QS@?'6*K_G3)-+C%HRR;%7:N9#R;PJC_`"Z1
MMM9QY5,8,I9DS1;(?*KNZM3&!71C&4.NNF*@CR;CPB3)^JZGU6'8/T?M;&Z.
MACN.S%*3\F1P;TQA%4\VZ]IS[I?U_H>M"#;)@83?8F(\_`?")YKPBYX1<\(A
M(Y_S'V%UW/-\KV$<>25HQG'K09*X[=8X:OHLP+U^+<R16UB5<Q`OREDUE@,(
MK*>V;DG(>G@*+<H[_P"ZK$\FY/%<<XJ6]V?$Z$0.=8-?'XH(W2:9RZ+720OK
M5[M)\/2E%]!.)>.>T+,<4XG+\G9B&QWM,V<W#&Y%S)1IN)6QZK<-E\O[H,I1
MC=0H[K6IT4N<>V+@.<$P@_#[1J<4`C^\O]>AP/FM-Y([X2!7;-M\-'[OWU;0
M[B[L$K_VJZ^*D_X*\V3SMVQ(HF-_9%FV_+_IQU#CI%8/A]I44[@_$QOP]`^8
MMWR7WPLC).W(V>N.RCD/T`73_<5FV/%?8))*&_U/(_U27TD;?I)M(_>$234F
MTYCN6$H&=SU&R,1DM>7LZ$PPE*XG5':#1I//FT2`PR2#<B*1HY-,2'](^Z7@
M_J-SSY;G@O-<@9_CJVR?)T,L&[W7%P)620"V<&-F>V+[H-:`/+#:&GB'BJ:U
M5,.X'!<<;<Y.N\5Q3-#<;*9;VSH9(K@W3'/?`QTOWQ<XD^875;7PGPT%*(:^
M2^_/2^L9LO.H>+JOL7G7>6K3=BIL/J33<"Y'@;Y8[M!,',B#,UJNT#7L>0U1
M/'H%D5K`K*'C4H4POTS+(^GU]?7%5X?2GUCY/TR2VCVNVQ>5V1W>WXRQ+Y@S
M9&520+-UC%,/)6&Q6B$Q/`SY#'0G5XF4M3M:1>MQ%HHK[#=`RR30CE<B"C]:
M3_V#J[_]Z9B_Z+#?A$[^S_P;3_ED/]T7PBR?")63KI*/_P!+O>*;@?2&(M7B
MB/'P`34;&PE`1^\0*/'[O"*UW=;T,X#[<Z?'6]&6;X8VUH4"O#X\S:SC!?1L
M_"D.X>,Z!EB';&2<V&HDD%SJ-':)OYC#*+*';^ZDHLU7(E*=?^SGN"^F\RS6
MM3NP'&5JS9J<BX^0I\;/RR]@8DJ*#E,BDSK!G18BK-VPC&8>L*K*G%!F4Q4%
M&L2JH*H$3[&,>Q[4_,VC%I[$,77Y:[:WT?$N1,OW&0A(TR]RK$3B>IR=PR%4
MYRH'73?1N0*U'1"R:L6J<IE%13,DH=!9%90B"?\`5C]?=YV_T&K>=,.P3ZPY
M9TKMTQE$\/"MUG%@E</V");L<IE@DFH?-+R-:4A(F>$A.3?)13KVP,J)"F(K
MX]%':;C[L^TDQ]:36*.+L=B6NP./=DJ&HZ1).Q]SA8]*.;Y`;QYU3.UZCDML
MT"2:.BE%%-THY9"85FBGA$:KPBB[+.7Z=AB%J\W<UGI4;EDS&F):XSC&Z3J0
MDKEE:Z0]'K+1!NJX:E.W1D)@'+LX&$R#%NNL!3>WZ1(MO4M]31D7,.M:*ZE+
MLQ3*\BU)N-)(M3*ID62*Y8F<@Y0%5%0IR@8H<E,`A\!\\E^>P<=V^PDO;1M]
M'35&9HQ(VH!&IA=J%0014=00?0O89M[/R6;,C'8WCL?)71*(9#&ZA(.EX;I=
M0@@T)H00>H6<$Y"C\0EXL0']H2#3_B^9/\RQWXB']=OY5B_RO)?AY_\`3?\`
MD70XLM<:)BJZGX1LD4.3*.)5BBF4`^T1.HN4H!_'R.7,8F!NN:ZMV,'RND8!
M[2Y2PX7,W#_+@M+E[S\C8GD^P-*R8F9B)YF61@Y6-F8\ZBR)'\2^:R+,ZK=0
MR+A(KIFJL@91!8@E.4#<E,`@/`AY+8Y"PR=N+O&SPW%J20'Q/;(PEIHX:F$B
MK2""*]"*%0W^-R.*N39Y2WFMKP`$LE8Z-X#A5I+7@.HX$$&G4&H2SOU`?3WD
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M`&*(>$5A3G(F0RBABD(0ICG.<P%(0A0$QC&,80`I2@'(B/P`/")8/HR9);$]
M@/=AV10OO.L5YIV6K&NV%K,"8A$W.KZZPSJOSUJ@7@_I/X632&&,DND)T3G]
MPOJ]:9P`B8BP)FVB;(X:QQG?&+MX]H&4ZM'V^J.9!!!J_4B9(IC(@^:MW3U%
ML\2,0Q%4P5/[9RB41Y`?"*.]Q=/L![TZ_P!]UPV.H\3=<>WB(=-0.\;(#-5"
M=!NJ6&N],ES$%W7;?67ARN&;Q`Q3`8HIJ`=!15(Y$A7].YC;()M&OJ+=?'-S
M,;71#`V5,;0N07`A_1260'6(-B*39[G$F.M\EZG%&:1#Z1]M3_"),O<-Z?;'
MPB_1R.0BA#)J%*<ARF(<AR@8AR&`2F*8I@$#%,`\"`_`0\(E>=I/IOH^)V3=
M;O\`4UL[8NN39EX\?RD[6Z]$*3N!;@]E5@<S#5:I-'*!ZO"6%S^I(17RTQ7U
M3@4R46B8O(D4TU"S_4]X_BPK%PQ7U1[`/F(?+MLE-,BYQQJ\F2)@!"2$U7&]
M=:1J;I8`]2A&;1FD!A'TE*'``1?6']+NX/9+<G779/LQSGJI3\$:P7"P90QY
MJ)J@PO\`+P4_E)U2+/2ZI<+Y;;Y&QS]\_IQ+4L[:',[D$45""5!NW,LHL)%<
M_/?67'YZS5<\N2677593M2D.9.$C:6TD7#,L5!QT.(*2KJ>;@L*QF(G#A`OI
M`W'QXY\I5R=V=VW)O(>0WU>9Y]FR^,1$,=HV1S/+ACBZRNF;6NBOY@I6G7TJ
M]O%'>U=\4\:8WCZRV]'?/L!,#-)>/C:_S9Y)ND38'4IKT_GFM*]*T4<EZ>*<
M```YXN_(?ZM7A"A_`/Y@/`?Q\U,=@V`^7<V1K_#P_;6XG_(KN(GIM3&4_B9O
M]M8CSIRJJR8@WSU:@/P/'SU+AWJ7/^T0DTU'CG\?(+CL#PLC:1;GO=7Z=I$\
M>P2M61;_`.1G/1NK+M2PT?H7DS#[3"[W(C6KN"AUPP[!XH&QDM00LG87Y9I.
M)"%!P2<F7DJ1,T>#V0!([<KKT"(*F`PEY^'/'EM.&.-#Q)L&VV1^]B]%O-.\
M2B+R=0FE=*!HUR4+=5"=1J17HJ;\Y\ICF7D6ZW\+,V!N8+=AA,OG:3#"R(GS
M-$=0[34#2*5IU]*L+YU1<A2XG8;T%MLS[-0?8?UV9S/HMOU7Y<L_,6V-B%7V
M),OR9BE0?.\A5J,3.M'3$\R$S>7=(M9!E-MS&+(1SE90[CPB(9CZ@[M9QQ&^
MUX[),!:29-H.0JE*4;-$_AO,&67$!<(1_&+MG#MIB*^X-CG$8ZD7)4S@1*U@
M=@N/S#9<ITDP`B&1K_U%]CO5M,VZN=6.YV'KUJI:+%(6F,U#WUJ-ZF8''4I*
M.E%Y#^@\N8G=*6EE\T42@H!8YHW<&#W72#ER(N3$5C;_`*A]O^Z\(OBS;W;7
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MXX&:9J&0-(L(1R_;D.(IGYY`2*XV'>K_`%'P#H=?>NO$=-E*7@#*.+LFXOR$
L[C98A\BW!/+],?T:_P!YGK>Y9+C(7^8AI`0(].W%!K[*"*#=-J@BW(1?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g94463g75p68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g94463g75p68.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`+`"(`P$1``(1`0,1`?_$`*,```$$`P$`````````
M``````H`!P@)`P0%"P$!``(#`0$```````````````((`P8'!000```&`@$#
M`@0"!0D)``````$"`P0%!@<("0`1$B$*,1,4%4$B48&1,A9A<:%"@B07MSF2
M-#5U=K88.'D1``$#`P,"!`,'!`,```````$``@,1!`42!@<A$S&Q%`A1(G1!
M88&1,G,)TB/3U'%"8__:``P#`0`"$0,1`#\`/XZ(HH;2;TZ?:40;&?VJV*Q;
MA)M+D.I`Q=QLC9.VV<J9E"*?PE1HX']TMADU$C%,$:P="4P=A[#Z=$5?+GW!
M''4C'JSJ#C;&1J:)3*C=&&BVWJM3.U+W[O4YE7#B")V?B'D"G;Q$OJ'IT1.=
M@?G4XE]D)F!J^,MWL0A<;--1U:@Z5?EK#B:W2=DEGR47&5]A`90@ZB^D)A](
MKD020;E5.HL<"%[F'MT13_M^Q>"\?VE>E7G*M+J-I;LF4BM#6*:;1#DK*0!0
M6;D#OA10.FN"1NWB<1#MZ]NN>Y[ECC;:V9=M[<F;QUAFFQL>8IY6Q.T/KH=\
M]`0:'P/_`"NE;=X=Y2W=@F[EVO@<GD,$^1\8FMX73-UQTUMHRK@6U'B!X]*K
M3+L]KB<H&+G?$8@/P'_$&K!_0,F`AU@',G$KA4;FP5/KK;_(OH/!_,C30[5W
M#7Z"Z_Q+&OM)K:V(*BV>,2%(`=^Y;_65!_3Z%3DCF']G4).:.(H6ZI-S8(-^
MMMSY2%3BX+YGF=HCVKN`N^@N1YQA;D7L?@B:I60<D1>5:8\H&*8N3F\C7).7
M1+6J=#0L,XL,O*3<PIX,FT?&P;51TNKYB1-$AC&$.P]>_M/?FSM]17$^S\C:
MY&"UD#)70.UM8]S=0:7#H26]>A*UW>/'F]^/I;:#>V,N\9/=Q.DA;<,T.>QK
MM+G!I.H`.Z=0%"-IS;\1KUTBT0Y$M42J+J%226=9:KC!B90P@`%&2?.6\<0>
MX^ODJ';\>MM6F*Q''F3,<Y=J<;?,47ZEY-H\R4QXBXX_M$)<:O)E3$`4%A/U
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MNS2%L<WS5$R$%,OF`B00,)%6]?>;[BXH-BF*F.UU<R/8*ZY49S[+`='RIL8W
M@W2)SIKMY>9P31LAP,:N@HF8ITUG1#E,`@(=P'HBZ.`.:SB[V<R+`8?P]M[0
MY?+5HFTJW7L96B#ON-KW,6%8#F2A(^M9)J53DWDFH1,1!%,AC]@^'1%R^9KD
MM@N++2*Z[`)1S&SY=LLFRQ;KU17WS%&]KR]:6KY6(5DFK=1)VYKM3BX]W,2*
M:1B'<H,OI2*)JN$C`1,MQ4<6</A6IPVX>Z:+?8[DOSU#1U^S3G+*;-I:IK&#
MNQM4)5GAS$3>3:J1^.JK06;@D>H6)1;"Y<)*^)BLP;-D"*\?HBHRY2.*'7K8
MFYZP;9TS#%>B=G=?MP-5;\O>*+4FC6RY!QVRSI2V5YK-^+#MDOXFBHJ#DE9=
M)\\(LYC#1PF(JFW.X(<BF_G;C]Q-L/E!YE"]VB^M'SN$AH,(>MOX2.8)HPQ'
M!$E_G/(.3=G56!P/D'D`!V].JT<E^UO8W*V\Y-Y[EO,FRY?;10]JW?#&P"(.
M`-7PR.).KKU`^"M1Q7[MM_\`$&QH]C;6L<3):QW4T_>N&322$S%I+:,FB8`W
M3TZ$_%-H'$QJUV#RD,K''MZF&X18"/\`*(%K``'6GCV-\+TH9<V3]5'_`*ZW
M8^_[G2O2'``?22_[*QJ\2VKQR"5*5RR@;\#DMT.<0_LJU50H_LZB_P!C7#);
M2.?.,=\1=1'SMB%)G\@'.;75D@P#V_`VDP\KH%20UXU#QSKK5L@TF$?2]TJV
M1GQ',W$7M"$EVRC,8<85U$.6[>+9LI*,?LS&*LFNB8JA3"4P"41#KLO#O"FW
MN%K&_P`=MVZO+FUO[EDQ]08RYA8SMAK3&R,$$=>HK5</YNYWW)SKD,=E-S6E
ME:WF.M7PM],)&M>'R&0N<V220@@FG1U*)SK9KY@>]T>2QG=,+8JM..YB-6AY
M2C3V/ZK)U1[%N$3-U6*\"[BE8TS<R)A`"_+#Q_#L(!UV1</0.^O<+:.$OW,\
M)HWKY,V!OI+O<SA+$VPJ^E9"0KE40R#!6U>NOH-N\<N2I2^-<ET]ZP9/3"9V
M>M+F;.#JF$%.B(@WW+\-&3'"1O$,DR;/#1-;Q7,QQG""2QF<FSSMC`C=ZV%0
MIA0<IIKG*"A>Q@*<P=^PCT1<CVQ$8QC.$72WZ%L@V^X,LRR;P44B)BY?.\^Y
M0^>Y7$@`*JZ@)E`3&[F$"@'P`.B*_'HB$T]RU5X*>V;X&#RL6P>JK\CE6@5C
MNFB#@5H:3N&&W,A&+"J0158NUHY(5$3=TS^/J`]$39^[[VPR-B+"VF6LT3;K
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M>B(Y+HB71$NB*M;9CD7A]:LP/<62^+9"TI-J_`SI)R.MC&,5/]Z(Z.9L:+>Q
M*I0^G^G]#@X_-W^`=5"Y@]V-AQ!OV395_A9;UC+6&831W+(R>Z''3VWQ'].G
MQU]:^`5TN$_9SD>:N.XM]X[.PV#Y+R>`P26KY0.R6C4)62C]6KP[?2GB4RY>
M8W'0@`FPM>`'\>UEK)B_J,/B(A^KKGK??YM,CKM[)5_?M_/HNE'^.;>(-&[E
MQ9'T]R%C6YC\?%+W1PI=#G[#V!6TUM$@C^@3E27$/]D>HR>_W:K1\FW<B7??
M<VX'YT/DI1_QR[N<ZDFYL:!]UK<./Y5;YJ:6G^VC;;.!O-A9TE6DMJ?86$$D
MV7L",^O(`]BR2(N5%&\9')-!3$WAX!\SO\?+\.K"\"\Y0\XXS)92WQSL=#87
M3(0UTXF+]<?<U$MCC#:>%/F^-56OW$<`3\`97%XBYR;<G-D;.2<N;;N@;'HE
M,>D!TDA=6E=7R_"B?^Q9>Q-3S2Y+;E#'=7/7TA7GR6*ZUJ$-"(@V3>BM+EDY
M-L,:D#-4JPF6\`^48#?NB`]=\5=4*+@3$SOE@]PJYY.L>,7LCHAH?CAOA;$.
M:%6JK6J;$9JAXBY1TDOBMTNF!+=2ZG8LDRSA6;:"HQ/]K9?*.;ZPHD(K./<E
M_P"B/OI_T/C7_/?%?1%P_;+_`.B+I!_R/+O^?N4^B*^+HB%3]R%_[,\"?_TR
MI'_=&*>B*V;ESXN,4<L>ITQKW?I8]*NL#*EO.%,J-6!9)YCO([*/>1[5X\C_
M`)K928JDZP>J,I9@"R1EVR@*)G(X004(1`M:^<@G+E[8O+K/5+<3%LMF74ES
M*K&J57F)I^\I3Z"^I,=Y9M7<S'8O&T,51-3ZAU7'R!D$E3"#AA'N53N.B(_+
MCUY+-3.3?#:>8]6L@%GDHXS9E?<>6!%*%R;BZ=<IG.2$O-5%PY49"X!(XM'S
M91U&2!"&,V<J@0_B1#">\FP#D&&J.CG(9C)L],_UCRB]I5JE&C<RZ=:/:)>M
MW?%UFD!)^9M&LKM2UV(JF$"?5R;9/OY*EZ(BP=&-NL;[V:GX1VHQ9)M'U;RS
M2(J:?L&RZ:SBJV]!$&-VI,LF0YS-IBHVELZ8+D-ZB*('+W(<AC$4L^B+F3,U
M#5V-<S-@EHR"B&8)"\E9E^UC(UH"ZZ39`7+YZJ@U0!9RL1,GD8/(YRE#U$`Z
M(N%(X\H$Q,*6&7H]0E9]5%!LK-R5:AGTNHW:@8&S<\BZ9*O#(-P./@3S\2]Q
M[`'?KP;O:NV+^_.5O\;83Y1S6M,TEO$^4M;72TR.87T;4T%:"IHMBL]W[LQV
M.;B,?E,C!BFN<X0QW,S(@YU-3A&UX9J=0:C2IIU6X6G5$A0*6JULI0^!2P<8
M!0_F`&H`'6<8#`@4%E:`?LQ_TKYCN/<+CJ=?WI/[\O\`4L:U'I;D@IN*A5W"
M8AV$BU?B52"`_$!*=H8HAU&3;FWIFZ);"R<P_88(B/R+5.+<^Y87:X<C?,>/
MM;/*#^8>LE=IU1J(/RU.K5RL%E'";J3+7H2-ABR#I)($4G+XL<V;%=+IHAX`
M<_D8"^G?MU+%8#!8(2C"65I9B9P=)V(8XM;@*!S^VUNIP'0$U-.BAF-Q[AW"
M8CG[^\OC`PMC-Q-),8VDZBUAD<[2TGJ0V@KU0LWN4.$M[NK18W>?5"GQ#G=+
M7B/:2\[4TH",EO\`R+QM4U2RR-=?0;]F\B[3?Z45L96(0=H+EF&`K12I5N[%
M-+UUXRG9P1<N&(.3C5V)A&T75L5;-8$@H6H9VP'",&M98P1X](L/'WK'E72(
MW!MC.Q+M1*FW1(/V)[Y1Z_[K=9R1.+[@>BR^1>&CD!KL&U6>OVN$PN0MVY#J
M+&88XN=4R),*$(0#',"$15ESB`!^Z4>B*-'M7,@1%YX4=8H^-<(JOL<V3-V/
M["W3.4ZC"6:9@N-F;MW`%$135<5^TL7(%'L/RW!1^`AT1$1]$0M7.FT1S%R>
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M5G;!N+=E\.Y%P)FRHQUZQ5E6KR-0NU6E"G^GDXB1(`"9%=(Q',?)Q[E--TR=
MH'3<,WB*2Z)R*ID,!$&+C;1+F(]N]FN[V#02E2'(]QPY$L:MFM.O:4HFTR]4
MCG(*!9)K7$"&DFF0(^)9HM!G*XSE6,V@BG]PC$#$;@@16QT[W+FH2D.W3SAK
M#R$ZZ7Y)("3-`OFH^1)AVRD2?E7:1\K56\FE(MRJ!V(JN@R.<.PF2(/H!$SE
MZY-<O<JV;===1]/](MN:UK#,9\Q#D#;':C/V')G$]*:X>Q-=HS*$C1J:A."H
M1T[NTO3V+-9RNY2="W5,V39*?4&61(K.-JFG(.KGJ04UL5LQ,<?PQ6@0\76/
MTZ]]Z!-Y]W^6E;3_`%`./+Y?S!*'B/IVZI'S9#[IY.397<1&\&TO1V^FCK(0
M=VCN[071K6NG5045]N!Y_:)'Q1"SFAMD=Y^NN=7R7YN.S5G:J;0:=--6FIKX
MIJTV',6)"_WR%#T^"KK"7G_:\4Q#OUI++;W]EOZ[?\78BODM[?=?QSAQ_MW/
MX-S5/-:SYCS%`@?N[8&#L/\`PYUA$''P_J>92^OZ.W6&YMO?UVS\\5*?]'8C
M5^'3Q6>UNOXY^Z/[<P/_`*-S6G\>JFAHVAM,A7\CAM.>QGL1K1&#5AGUZVNG
M]F^SD!Y]L&L',Q*V^O[^0#V-Y=6%]M\?-,>+RXYI-V<KZV/TW>,!':[7S]OT
MYT:=?C]ZK9[H9>"9<OACP2+,8<6,OJNPVX:>]WCH[OJ0'EW;\*=**='5DU5I
M"+<I_"+LGC#:QARU\+$NQQUMI"2;ZS9DU\;NH^#J><S.S`ZM$A`-'[J-K3V0
MO2*1D['79!5NRG5#`\;+MY,O=R164:K<M6/=GL./J#N[J7M'J1F)_7WU$S1A
M[*NK.PL[C*P*RK!S!V@E(R-7\;35<GZ5.(++$!%^LS?(I*BD<BI2@X5(JA-;
M=4.0_P!O'L/EP=8<`9`Y#>*/8&Q_Q^>@8G=,7>RV!)@S;Y3"394>8592%MFH
M^`31CG@M2&:S[)FU575C':/RS$5O0\X54M46,?A?CJY4<HY4>(&)$8SD=,KM
MBI%*4,`%2;VW)&2'4)CNJ1:2P]G+T7[LJ)`$Q4U>W82+3T/T/V1N6X%QY6^1
M]"HPFU%GQY_A!KOK91)T;A1M-\'K.G;M[737(I2,KIEJV'?.#3,HR*#)/ZUV
MF@<Z;D$FQ%'/=/.W(OH7RO6?9_&&C.8MQ]$<V:MX7QEE1#`R$99LDTV\8GN&
M6IMC9*[5&SM>;6?P[+(;E-=HZ:MH^3;/B>#U)9MV`BE/#\Y6'[/')$JFB_*Y
M8+HX2_NV.4M`LN15B,\$OHR<S<\$5C]@(*?E,LM,D0('<PG[!T10FQ[QW;9<
MG/)-A_DRY',31^L6#=46;9/3W2N0L=?ON39"=CII>Q1F3<[35;6>U>!>#9`;
M2WVELNNY%9@Q:K%32:K*/B(HSHB71$NB)=$2Z(ET1+HB71$NB)=$2Z(ET1+H
,B71$NB)=$2Z(O__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
